Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Lenskart's Wild IPO Ride: From Listing Slump to Stock Surge – Big Move Ahead?

Consumer Products

|

Updated on 10 Nov 2025, 07:12 am

Whalesbook Logo

Reviewed By

Aditi Singh | Whalesbook News Team

Short Description:

Lenskart Solutions Limited, India's largest eyewear retailer, experienced a mixed market debut, listing below its IPO price of Rs 402 on the NSE and BSE. Despite an initial dip, the stock recovered to trade above the IPO price. The company's Initial Public Offering (IPO) was highly subscribed, attracting bids worth over Rs 1 lakh crore, demonstrating strong investor interest. The IPO aimed to raise Rs 7,278 crore, with founder Peyush Bansal among those selling shares.
Lenskart's Wild IPO Ride: From Listing Slump to Stock Surge – Big Move Ahead?

▶

Detailed Coverage:

Lenskart Solutions Limited, India's prominent eyewear retailer, faced a challenging market debut on Monday, with its shares listing below the Initial Public Offering (IPO) price. The stock opened on the National Stock Exchange (NSE) at Rs 395 and on the Bombay Stock Exchange (BSE) at Rs 390, both representing a discount to the IPO price of Rs 402.

However, the initial downturn was short-lived. By 12:20 p.m., Lenskart's share price demonstrated a strong recovery, trading at Rs 408, which is approximately 1.5% above the IPO price and 3.3% higher than its NSE listing price. This recovery signals investor confidence returning after the subdued opening.

The IPO itself was a significant event, attracting substantial investor interest and being subscribed approximately 28 times. The Qualified Institutional Buyers (QIB) category led the subscriptions with a 40.36 times oversubscription, followed by Non-Institutional Investors (NII) at 18.23 times, and Retail Investors at 7.56 times. The IPO aimed to raise Rs 7,278 crore, including a fresh issue component and an Offer for Sale (OFS) from existing shareholders. Founder and CEO Peyush Bansal participated in the OFS, offloading shares worth Rs 824 crore, while other major investors like SoftBank Vision Fund and Temasek Holdings also divested stakes.

Lenskart's business model, featuring a direct-to-consumer (D2C) approach and a robust omnichannel presence with over 2,700 physical stores and an online platform, underpins its growth strategy.

Impact: This news has a moderate positive impact on the Indian stock market and investor sentiment towards the retail sector. While the initial listing dip might cause short-term jitters, the subsequent recovery suggests underlying strength and investor belief in Lenskart's business model and future growth. The strong subscription numbers indicate robust demand for well-managed companies in the consumer segment. Rating: 7/10

Difficult Terms: * IPO (Initial Public Offering): The process by which a private company sells shares to the public for the first time, becoming a publicly traded company. * Listing: The act of a company's shares being admitted to trading on a stock exchange. * Subscription: The process where investors apply for shares during an IPO. A subscription rate indicates how many times more applications were received than shares available. * QIB (Qualified Institutional Buyer): Large institutional investors like mutual funds, pension funds, and foreign institutional investors, which are generally considered sophisticated investors. * NII (Non-Institutional Investor): Investors who bid for shares worth more than a specified amount (e.g., Rs 2 lakh in India), often high-net-worth individuals or corporate bodies. * OFS (Offer for Sale): A method where existing shareholders of a company sell their shares to the public during an IPO, rather than the company issuing new shares. * D2C (Direct-to-Consumer): A business model where a company sells its products directly to its end customers, bypassing intermediaries like distributors or retailers. * Omnichannel: A retail strategy that uses a combination of online (website, app) and offline (physical stores) channels to provide customers with a seamless shopping experience.


Healthcare/Biotech Sector

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!


Agriculture Sector

Godrej Agrovet Stock EXPLODES Upwards? ICICI Securities' Bold BUY Call & ₹935 Target Stuns Investors!

Godrej Agrovet Stock EXPLODES Upwards? ICICI Securities' Bold BUY Call & ₹935 Target Stuns Investors!

Godrej Agrovet Stock EXPLODES Upwards? ICICI Securities' Bold BUY Call & ₹935 Target Stuns Investors!

Godrej Agrovet Stock EXPLODES Upwards? ICICI Securities' Bold BUY Call & ₹935 Target Stuns Investors!